Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition

Oncotarget

Volumn 6, Issue 14, 2015, Pages 11820-11832

  Caffa, Irene ^a   D'Agostino, Vito ^b   Damonte, Patrizia ^a   Soncini, Debora ^a   Cea, Michele ^a   Monacelli, Fiammetta ^a   Odetti, Patrizio ^a,c   Ballestrero, Alberto ^a,c   Provenzani, Alessandro ^b   Longo, Valter D ^d,e   Nencioni, Alessio ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Cell cycle regulation; E2F transcription factors; Fasting; MAPK pathway; Tyrosine kinase inhibitors

Indexed keywords

CRIZOTINIB; ERLOTINIB; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; REGORAFENIB; TRANSCRIPTION FACTOR E2F; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; HUMAN; IMMUNOBLOTTING; METABOLISM; NEOPLASM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FASTING; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84931329276     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3689     Document Type: Article

References (28)

1. Krause DS and Van Etten RA. Tyrosine kinases as targets for cancer therapy. The New England journal of medicine. 2005; 353(2):172-187.
2. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC and Ciardiello F. Treatment of advanced non-smallcell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clinical lung cancer. 2014; 15(3):173-181.
3. Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24(10):2492-2500.
4. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863):303-312.
5. Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodriguez C and Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014.
6. Rolfo C, Bronte G, Sortino G, Papadimitriou K, Passiglia F, Fiorentino E, Marogy G, Russo A and Peeters M. The role of targeted therapy for gastrointestinal tumors. Expert review of gastroenterology & hepatology. 2014:1-11.
7. Marotta V, Sciammarella C, Vitale M, Colao A and Faggiano A. The evolving field of kinase inhibitors in thyroid cancer. Critical reviews in oncology/hematology. 2014.
8. Lovly CM, Yu HA and Riely GJ. Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014.
9. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R and Longo VD. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Science translational medicine. 2012; 4(124):124ra127.
10. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G and Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against highdose chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(24):8215-8220.
11. Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC and Longo VD. Fasting enhances the response of glioma to chemo-and radiotherapy. PloS one. 2012; 7(9):e44603.
12. Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M and Stahel RA. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC cancer. 2012; 12:571.
13. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, Kopchick JJ and Longo VD. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell stem cell. 2014; 14(6):810-823.
14. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P and Longo VD. Fasting and cancer treatment in humans: A case series report. Aging. 2009; 1(12):988-1007.
15. Laviano A and Rossi Fanelli F. Toxicity in chemotherapy-when less is more. The New England journal of medicine. 2012; 366(24):2319-2320.
16. Hine C and Mitchell JR. Saying no to drugs: fasting protects hematopoietic stem cells from chemotherapy and aging. Cell stem cell. 2014; 14(6):704-705.
17. Vichai V and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature protocols. 2006; 1(3):1112-1116.
18. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
19. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007; 445(7126):437-441.
20. Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A and Nencioni A. Ras-induced resistance to lapatinib is overcome by MEK inhibition. Current cancer drug targets. 2010; 10(2):168-175.
21. Trimarchi JM, Fairchild B, Wen J and Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(4):1519-1524.
22. Schaal C, Pillai S and Chellappan SP. The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. Advances in cancer research. 2014; 121:147-182.
23. Brandhorst S, Wei M, Hwang S, Morgan TE and Longo VD. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Experimental gerontology. 2013; 48(10):1120-1128.
24. Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR and Rattan R. Dietary energy balance modulates ovarian cancer progression and metastasis. Oncotarget. 2014; 5(15):6063-6075.
25. Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R and Pili R. Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget. 2013; 4(12):2451-2461.
26. Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Lopez IA, Dorca J, Martinez S, Lopez NB, Fernandez SD, Cuyas E, Visa J, Rodriguez-Gallego E, Quirantes-Pine R, Segura-Carretero A, Joven J, et al. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget. 2013; 4(9):1484-1495.
27. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F and Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature reviews Drug discovery. 2010; 9(4):277-291.
28. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C and Willems L. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. British journal of haematology. 2009; 144(1):41-52.